Chronic kidney disease (CKD) is a long-term condition in which kidney function declines over time, reducing the kidneys’ ability to filter blood and maintain fluid and electrolyte balance.
20/20 BioLabs began trading on Nasdaq under ticker AIDX and disclosed a contingent financing agreement of up to $40 million. It later signed an exclusive U.S. license deal with ROKIT to add CKD prediction to OneTest for Longevity.
20/20 BioLabs has licensed ROKIT Healthcare's chronic kidney disease prediction algorithm for its longevity platform, expanding from inflammation tracking to specific risk detection. The technology will be integrated into the company's OneTest for Longevity program, with potential applications for improving outcomes in regenerative treatments. The agreement includes revenue sharing and could lead to exclusive commercialization rights for ROKIT in East Asian markets.
Bayer's Phase III FIND-CKD trial shows finerenone significantly slows kidney function decline in non-diabetic chronic kidney disease patients. The drug met its primary endpoint with improved eGFR slope over 32 months, marking its fifth consecutive positive Phase III trial. Bayer plans to submit the data to the FDA for label expansion into non-diabetic CKD.
New research demonstrates RNA therapies can enhance heart regeneration after injury, while RNA biomarkers improve prediction of cardiovascular complications in chronic kidney disease patients.
China's NMPA approved Desidustat Tablets on March 13, 2026, for treating anemia in non-dialysis CKD patients. Clinical trials showed the oral HIF-PHI was non-inferior to erythropoietin in maintaining hemoglobin levels with improved quality of life.
New research demonstrates machine learning can optimize drug dosing, identifies biomarkers of treatment response, and validates prognostic criteria for long-term kidney survival in pediatric lupus nephritis patients.
Finerenone met its primary endpoint in reducing albuminuria in type 1 diabetic kidney disease, marking the first successful drug trial in 30 years for this population. Separately, SGLT2 inhibitors showed superior kidney protection compared to GLP-1 medications in type 2 diabetes patients.
A systematic review and meta-analysis demonstrates that semaglutide significantly reduces major adverse cardiovascular events in adults with type 2 diabetes, with particular benefits for nonfatal myocardial infarction and stroke.
A systematic review of 64 randomized clinical trials found GLP-1 receptor agonists produce greater weight loss in women than men, while the global market is projected to grow from $51.57 billion in 2026 to $112.62 billion by 2032.
Disc Medicine received a complete response letter from the FDA for bitopertin as a treatment for erythropoietic protoporphyria. The FDA acknowledged the drug lowers PPIX levels but requires evidence from the ongoing Phase 3 APOLLO study before approval.
| NCT ID | Title | Status | Phase |
|---|---|---|---|
| NCT07575347 |
Periodontal Disease in Rare Renal Disorders (PERIO-RA-RE) |
NOT_YET_RECRUITING | |
| NCT07572890 |
Adia Med of Winter Park LLC Chronic Kidney Disease Research Study |
RECRUITING | PHASE1 |
| NCT07496177 |
A Mechanistic Study on the Effect of HTD1801 Versus Placebo on Kidney Function in Patients With Type 2 Diabetes and Chronic Kidney Disease. |
NOT_YET_RECRUITING | PHASE2 |
| NCT07474441 |
Early Coronary Angiography in Advanced Chronic Kidney Disease With Acute Coronary Syndrome |
COMPLETED | |
| NCT07461012 |
Impact of Garlic on the Clinical Outcome in Chronic Hemodialysis Patients |
COMPLETED | NA |
| NCT07355062 |
A Study to Evaluate the Efficacy and Safety of Veverimer for the Treatment of Metabolic Acidosis |
RECRUITING | PHASE3 |
| NCT07312981 |
The CPH-MBD Cohort Dietary Substudy - Comparison of Methods for Dietary Registrations |
RECRUITING | |
| NCT07310849 |
Digital Care for Holistic Health in Older Adults With Diabetes and Multimorbidity |
ENROLLING_BY_INVITATION | NA |
| NCT07304817 |
Comparative Study on the Mode of Action of Vicadrostat and Spironolactone on Protein Profiles and Renal Hemodynamic Effects (COMPARE-VS) |
RECRUITING | PHASE2 |
| NCT07268807 |
Effect of Roxadustat on Heart Failure Patients With Anaemia and Moderate-to-Severe Chronic Kidney Disease |
NOT_YET_RECRUITING |
